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Several alternative genetic pathways lead to colorectal cancer
(CRC), but in all cases result in the cell escaping from signals
which control cell proliferation and differentiation. Approximately
20% of CRC cases arise due to an inherited predisposition. The
principal inherited forms are hereditary non-polyposis colorectal
cancer (HNPCC) caused by mutations in DNA mismatch repair
genes (mainly hMLH1 and hMSH2; Fishel et al, 1993; Leach et al,
1993; Bronner et al, 1994; Papadopoulos et al, 1994; Liu et al, 1996)
and familial adenomatous polyposis (FAP), which arises as a result
of mutations in the tumour suppressor gene APC (Groden et al,
1991; Nishisho et al, 1991). However, the vast majority of CRC
cases are sporadic and arise due to random somatic mutations.
The genes involved and the order of genetic events in the genesis
of sporadic CRC tumours have not yet been elucidated. Several
mutations in the APC gene have been identified in sporadic
colorectal cancer (Cottrell et al, 1992) and somatic mutations in
the hMSH2 and hMLH1 genes have been identified in a small
proportion of sporadic tumours displaying microsatellite instab-
ility (Liu et al, 1995; Konishi et al, 1996). Mutations in several
other candidate genes, such as the serine/threonine kinase STK11
(Dong et al, 1998) and the tyrosine kinase c-SRC (Irby et al, 1999)
are also thought to be predisposing factors in sporadic CRC. 
In this paper we have investigated the role of the caudal
type homeobox gene, CDX2, in sporadic colon cancer. CDX2 is a
transcription factor known to be crucial to the normal proliferation
and differentiation of intestinal epithelial cells (Duluc et al, 1997;
Lorentz et al, 1997). In the mouse, Cdx2 is expressed in the gut
from its earliest formation at 8.5 dpc and is confined to the poster-
ior gut endoderm during late development (Beck et al, 1995). In
adults Cdx2 is found exclusively in intestinal epithelial cells, most
abundantly in the proximal colon (James and Kazenwadel, 1991;
James et al, 1994). Several CDX2 target genes have been identi-
fied, such as the small intestine gene sucrase-isomaltase (Suh et al,
1994) and calbindin-D9K (Lambert et al, 1996) and the colonic
gene carbonic anhydrase I (Drummond et al, 1996). 
CDX2 has been implicated in disorders involving abnormal
intestinal differentiation and neoplasia. Our studies and those of
others, have demonstrated that CDX2 and its target genes are
markedly down regulated in many colorectal carcinomas in rodents
and humans (Sowden et al, 1993; Ee et al, 1995; Mallo et al, 1997,
1998). In addition, studies of Cdx2 null mice have shown that while
complete deficiency is embryonic lethal, Cdx2 heterozygous null
mice develop multiple intestinal tumours. The polyps are predom-
inantly located in the colon and do not express Cdx2 from the
remaining wild-type allele (Chawengsaksopahak et al, 1997; Beck
et al, 1999; Tamai et al, 1999). These observations led to the
proposal that the loss of tumour suppressor function of the CDX2
gene could be involved in tumorigenesis. 
The polyps which arise in the Cdx2 +/– mice are unusual; their
gastrointestinal phenotypes appear to vary. Tamai et al (1999)
described two forms, cecal/colonic villiform structures and colonic
hamartomas similar to the Peutz-Jegher polyps. These structures have
been ascribed to a homeotic anterior transformation of the gutmucosa
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due to Cdx2 haplo-insufficiency and bi-allelic Cdx2 inactivation,
respectively. Beck et al (1999) proposed that the colonic lesions were
composed of heterotopic stomach and small intestinal mucosa and
Chawengsaksopahak et al (1997) described a cell structure very
similar to oesophageal epithelium. Homeosis due to Cdx2 deficiency
was proposed as the cause of the abnormal cellular differentiation. 
The human CDX2 gene is localized to chromosome 13q12–13
(German et al, 1994; Drummond et al, 1997) and it is of interest
that chromosome 13 abnormalities have been reported in a number
of CRC cases (Lothe et al, 1992; Bardi et al, 1995). These factors
taken together make CDX2 a strong candidate for investigation in
the context of sporadic CRC. In this paper we report a genetic
analysis of CDX2 in sporadic CRC. All exons and exon/intron
boundaries were thoroughly searched for DNA polymorphisms
and rare variants in a panel of CRC tumours and normal control
samples. Various polymorphisms have been identified which have
enabled the assessment of loss of heterozygosity (LOH) in
tumours and an evaluation of the relative mRNA expression of
both alleles in tumours. In addition associations between genetic
variation and tumour progression were looked for. 
MATERIALS AND METHODS 
Subjects 
Flash frozen or paraffin-embedded tumour and corresponding
normal colon biopsy material from a total of 51 unrelated sporadic
CRC cases were collected from St Mark’s Hospital and the
Hammersmith Hospital. The sporadic CRC cohort comprised 19
females and 32 males ranging in age from 37 to 96 years (mean
age = 69 years). 4 of the cases were of Asian origin, while all
others were Caucasian. Except in 6 cases, each tumour sample was
examined histologically and the degree of dysplasia recorded. 18
were characterized as adenocarcinoma of the rectum, 6 as sigmoid
adenocarcinoma and the remainder were grouped together as
adenocarcinoma of the colon. 4 tumours showed features similar
to gastric mucosa. For 32 tumour/normal pairs the Dukes’ stage
classification were available, of which 9 were stage A, 12 were
stage B, and 11 were stage C. DNA samples from 60 unrelated
individuals from the Centre d’Etude du Polymorphisme Humain
(CEPH) collection and 50 unrelated British subjects were used as
controls. 
DNA and RNA preparation 
Normal and tumour biopsy material was ground to a fine powder
under liquid nitrogen. The available biopsy material varied consid-
erably in weight but was divided approximately equally and used
to prepare DNA and RNA. Genomic DNA was extracted using a
procedure based on the protocol described by Goelz et al (1985).
Ground tissue was incubated overnight in 500 µl lytic solution
(1% SDS, proteinase K (0.5 mg ml-1) in 13 TE buffer (pH 8.0))
at 52˚C. This was followed by extraction with equal volumes of
Tris-saturated phenol (pH 8.0), followed by phenol:chloroform
(1:1) and then chloroform. DNA was ethanol precipitated at
–20˚C, washed with 70% ethanol, dried and resuspended in 1 3
TE buffer. Total RNA was extracted from the ground tissue
(between 60 and 100 mg) using 1 ml of RNAzol™ B (Biogenesis
Ltd) and homogenizing in a hand-held glass micro-homogenizer,
according to the manufacturer’s instruction. RNA was precipitated
with isopropanol and resuspended in 30 µl of 1 3 TE buffer. 
PCR amplification 
10 pairs of primers were used to amplify CDX2 (Table 1). PCRs
contained 50 –100 ng of genomic DNA, 0.5 mM dNTPs, 0.5 µM
forward and reverse primers and 0.5 units of Taq DNA polymerase
Table 1 Primer pairs used for PCR amplification of the CDX2 gene 
Primer pair Region Primer sequence (5¢–3¢) Ta (˚C) Product size (bp) 
15 ¢-UTR F: GCCTGTGCGGGTCTTCCCCG 60 324 
R: CACGGAGCTAGGGTACATGC 
2c Exon 1 F: GGACTACGGCGGTTACCACG 59 129 
R: CGTAGCCATTCCAGTCCTCC 
3 Exon 1 F: GGAGGACTGGAATGGCTACGC 67 303 
R: TGCTGCGCCGGCTTCCGCATC 
4 Exon 1 F: GCTGCCGCCGAGCAGCTGTC 75 178 
R: CTGTGCGCACTGGACGCGCG 
5c Exon 2 F: CAGACTTGGCAGGAACCAGC 65 342 
R: CATGGTCCTCTGCCAGGCAGTG 
6c Exon 3 F: TCAGAACCGCAGAGCAAAGGAGAGG 59b 126 
R: CTCAGAGGACCTGGCTGAGG 
7 Exon 3 F: CTTGAGTCCGGTGTCTTCCCTG 56 218 
R: GTCTGTAGGTCTATGGCTGTG 
83 ¢-UTR F: GCTAGACTCCTCAGGAGAGAC 59 224 
R:AGGCAATGCTTCTGCCAGTCC 
93 ¢-UTR F: ACTGAGGAGACAGAAAGCCTCCa 55 257 
R: CCGCAGTGTAAACCTTGCCTGa
10c 3¢-UTR F: GCTTGAGGCCAAGATGGCTGC 51 283 
R: GCTCTCTAACAAGTCCTGTTC 
a0.6 µM of primer was used in PCR amplification. bPCR was cycled initially at a Ta of 64˚C for 5 cycles and then at 59˚C for 30
cycles. cPCR amplification required 5% formamide. 220 S Sivagnanasundaram et al
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(Advanced Biotechnology), in either Buffer I or V (Advanced
Biotechnology). Primer pairs 2, 5, 6 and 10 required the addition
of 5% formamide to the reaction mix to improve specificity. The
PCRs were performed at 96°C for 5 min followed by 35 cycles of
96°C for 30 s, Ta°C (see Table 1) for 30 s and 72°C for 30 s. A
final step of 72°C for 5 min was also carried out. PCRs using
primer pair 6 were cycled initially at a Ta of 64°C for 5 cycles and
then at 59°C for 30 cycles. 
cDNA synthesis and PCR amplification 
5 µl of total RNA extracted from tumour and normal tissue
samples were used to make cDNA. RNA RT-PCR was carried out
using random oligonucleotide primers (Amersham Pharmacia
Biotech) to generate first strand cDNA. Control RT-PCRs were
performed across exons 2 to 4 of the ubiquitously expressed phos-
phoglucomutase (PGM1) gene to assess the quality and quantity of
the cDNA [PGM1 2F: GAAAAATCAAAGCCATTGGTGGG and
PGM1 2R: GGCACCGAGTTCTTCACAGAGGAT]. This also
served to confirm that there was no contamination of RNA by
genomic DNA. The possibility that the RNA samples contained
DNA was also checked by RT-PCR in the absence of reverse tran-
scriptase. cDNA PCRs were set up using conditions optimized for
the respective primer pair (see above and Table 1). cDNA PCR
amplification from exon 1 to exon 2 was performed using the
Ex1F: GCTGCCGCCGAGCAGCTGTC and Ex2R: GGATGGT-
GATGTAGCGACTG primers at an annealing temperature of
61°C. 
Single strand conformation polymorphism (SSCP)
analysis 
PCR products were prepared for SSCP analysis in formamide dye
(98% formamide, 20 mM EDTA, pH 8.3, 0.05% bromophenol blue
and 0.05% xylene cyanol) denatured at 95°C for 5 min and rapidly
cooled on ice. Samples were analysed by vertical polyacrylamide
gel electrophoresis (18 cm 3 16 cm 3 0.75 mm, Hoefer SE 600
series, Amersham Pharmacia Biotech) in 0.5 3 TBE buffer. Each
fragment was analysed under a number of electrophoretic condi-
tions: the polyacrylamide gel was either 10% or 12%, with or
without glycerol, at either room temperature (RT) or at 4°C. The
running conditions were also varied between 100 to 350 V for 2.5
to 17 h. In one case the addition of 20% formamide to the gel (frag-
ment 3) improved band resolution. After electrophoresis, the gels
were washed, fixed and stained as described by Harvey et al (1995). 
Sequence analysis 
PCR amplified products were sequenced either automatically using
the ABI sequencer 377, BigDye or dRhodamine terminators and
AmpliTaq DNA polymerase FS (PE Biosystems) or manually using
33P-labelled ddNTPs and the Thermo Sequenase Radiolabelled
Terminator Cycle Sequencing Kit (USB Corporation) to confirm that
the correct sequence had been amplified. Products showing variant
SSCP banding patterns were also sequenced. 
Phosphoimaging 
cDNA samples were manually sequenced using 33P-labelled ddNTPs
and the reaction mix resolved by electrophoresis on a 6%
denaturing polyacrylamide gel. The gel was dried and exposed to a
phospho-imager screen for 1 to 2 h. Signals of individual bands were
quantified using the Fuji X-BAS-1000 phosphoimager. The amount
of radioactivity, expressed as a photo-stimulated luminescence
(PSL) value and density of radioactivity over a fixed area (PSL/mm2)
were obtained using the MACBAS software. The relative amounts
of the two alleles were determined taking into account the back-
ground signal and inter-lane signal variation (see caption to Fig 3). 
Statistical analysis 
The significance of differences in allele frequencies between
control and CRC patients was assessed using the 2 by m c2 test.
The Monte Carlo c2 ‘Clump’ test was used to examine the
differences in haplotype frequencies between control and patient
subjects and to assess the association between haplotype and
Dukes’ stage assignment (Sham and Curtis, 1995). A three by
three  c2 test was used to test for association between haplotype and
Dukes’ stage assignment. 
RESULTS 
Sequence of the human CDX2 gene at exon/intron
boundaries 
Since genomic sequence for human CDX2 was not available in
current databases or literature we began by determining genomic
sequence at each exon/intron boundary. Comparison of the human
CDX2 cDNA sequence (accession number Y13709) with mouse
Cdx2 genomic sequence (accession number U00454) identified the
positions of the introns and defined the sizes of the three exons as
541 bp, 146 bp and 252 bp. The sizes are in agreement with those
reported by Yagi et al (1999). Primers designed from cDNA
sequence close to the predicted splice sites were used to determine
intronic sequence adjacent to each exon. The genomic clone,
lgCDX2.3, which we have described previously (Drummond et al,
1997) was used as template for this analysis. The exon/intron
boundary sequence information compiled in our study has been
deposited in the EMBL database (accession numbers Y13709,
AJ278431, AJ278432 and AJ278434) and used to design 10 pairs of
primers across the CDX2 gene which amplify the 5¢ and 3¢-UTR
regions, coding sequences and exon/intron splice sites (Table 1). 
Polymorphisms in CDX2
PCR amplified products (Table 1) from DNA samples were
screened for polymorphisms using a combination of non-
radioactive SSCP analysis and direct sequencing. 
6 polymorphisms and one rare variant (C1769T in the 3¢-UTR)
were identified; all are due to point mutations (Figure 1). Two adja-
cent bases in the 3¢ end of intron 1, -32 and -31, were both polymor-
phic, C-32T and A-31T (primer pair 5). These variants gave rise to
six SSCP patterns (Figure 1). Sequence analysis showed that 3 of
these could be ascribed to homozygosity at both sites, -32C/-31T;
-32T/-31T; -32C/-31A, while the others were due to heterozygous
combinations -32CT/-31AT; -32C/-31AT; -32CT/-31T. Two other
variant sites T1239C and G1314T were also found together in a
single PCR product encompassing part of exon 3 (primer pair 7) and
these in combination gave rise to 3 SSCP banding patterns (Figure 1).
Sequence analysis showed that two of these patterns could be
explained by homozygosity at both sites 1239T/1314G andCDX2 and colorectal carcinoma 221
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1239C/1314T. The third pattern was due to a heterozygous combi-
nation of alleles 1239TC/1314GT. The T1239C change leads to a
Ser to Pro substitution at codon 293. This codon is Pro in both mice
and hamster (German et al, 1992; James et al, 1994; Suh et al, 1994).
A further variant G1655A (primer pair 9) was found in the 3¢-UTR
which leads to a loss of an Mwo I site. Finally a silent base change
G545C (primer pair 2) was found in exon 1 at codon 61. 
Allele frequencies were estimated for all 6 variants in cohorts of
control and patient DNA derived from normal tissue biopsy (Table 2).
c2 tests found no statistically significant difference between
control and patient allele frequencies (P . 0.05). 
The polymorphisms C-32T and A-31T lie in a potential RNA
splicing branch site (TTGCAGT) upstream of the splice acceptor
site of exon 2. Since mutations in branch sites are known to alter
RNA splicing (e.g. BRCA1; Li et al, 1999) we investigated whether
these mutations affected splicing at the exon1/exon2 boundary.
PCRs across exon1 to exon2 were carried out using cDNA prepared
from normal tissues representing the 6 different genotypes (3 of
each, see above). A single amplified product of expected size
(190 bp) was obtained in all cases and sequencing of this product
confirmed that there were no changes in mRNA splicing. 
Within the CDX2 coding exons there are 3 regions of imperfect
trinucleotide repeats encoding a stretch of 8 polyalanine, 13
polyhistidine/proline and 7 polyglutamine residues. Though imper-
fect these regions were searched for variations in repeat numbers
but none was found. 
The G545C and T1239C polymorphisms have recently been
described by Yagi et al (1999) and Wicking et al (1998). The
frequency of the 545C variant in the Japanese population (Yagi et al,
1999) was higher (0.11 sporadic CRC samples; 0.07 controls) than
in our UK population (0.04 CRC cases; 0.06 controls) while the
frequency of the 1239C variant was very similar in both populations.
It was not possible to estimate frequencies for the 545C and 1239C in
the Australian population from the data reported by Wicking et al
(1998). The Lys164 and Leu260 variants which have been reported in
the Japanese population with a frequency of around 0.01, were not
found in the UK population. As in our study of UK sporadic CRC
cases, the Yagi et al (1999) study also found no difference between
control and patient allele frequencies. 
Mutations in CDX2
In addition to screening for polymorphic variations, the DNA from
the CRC tumours (n = 51) was thoroughly analysed for rare muta-
tions by SSCP. Only one rare variant, an A1408G substitution in the
3¢-UTR (primer pair 8), was found in a tumour sample that showed
features of gastric mucosa. This variation was also present in the
DNA from the normal adjacent tissue but was not seen in 47 controls. 
Haplotype analysis and loss of heterozygosity 
Amongst the 51 patients with CRC, 42 were genotyped for all 6
polymorphic sites. 13 were homozygous at all 6 sites and could be
(B)
(A)
G545C (codon 61) C-32T, A-31T T1239C (codon 293), G1314T G1655A, Mwo I site
GC G C T C C CT CT 32
TT A T A AT T 31
TC G G TC A 1239
GT A GT 1314
C1769T A1408G
3'-UTR (743bp) exon 3 (255bp) exon 2 (146bp) exon 1 (541bp) 5'-UTR (304bp)
~1.4kb ~4.8kb
Figure 1 Structure of the human CDX2 gene. (A) A schematic representation of the genomic structure of the human CDX2 gene. Solid box – coding exons;
speckled box – non-coding regions; hatched box – homeobox (183bp); dotted line – introns, approximate sizes of introns in kb as estimated by Yagi et al, 1999;
the transcription start site is indicated by the arrow in the 5¢-UTR; the location of the polyadenylation signal is indicated by a bar beneath the 3’-UTR.
(B) Polymorphisms and rare variants identified in the human CDX2 gene in the course of this study. For each polymorphism (indicated by arrows) SSCP
banding patterns are depicted and the genotype shown. The location of two rare variants are indicated by arrowheads (SSCP not shown) 
Table 2 Variant allele frequencies at the six polymorphic sites in control subjects and sporadic CRC cases 
Polymorphisms Alleles Controls CRC  cases
CEPH British normal tissue 
(n = 60) (n = 50) (n = 51) 
G545C, codon 61 C 0.04 0.06 0.04 
C-32T T 0.33 0.27 0.38 
A-31T T 0.78 0.83 0.80 
T1239C, codon 293 C 0.16 0.10 0.18 
G1314T T 0.16 0.10 0.18 
G1655A, Mwo I site A 0.47 0.49 0.40 222 S Sivagnanasundaram et al
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categorized into 3 common haplotypes (haplotype I, II and III;
Table 3). Genotype analysis of the heterozygous cases revealed
that they could be explained either as a combination of common
haplotypes or as a combination of one of the common haplotypes
with a rare haplotype. In this way complete haplotypes were deter-
mined for 84 CRC chromosomes and 158 chromosomes from
CEPH and British controls. 6 rare haplotypes were identified in
total (IV–IX). Haplotypes I and II accounted for approximately
70% of all chromosomes in the control and CRC patient groups.
The observed differences in haplotype frequencies were not
statistically significant (P . 0.05) when results of a 2 by m table, a
collapsed table and a clumped 2 by 2 table were analysed. 
28 of the tumour/normal pairs were informative for LOH, that is
the normal sample was heterozygous for at least one polymorphic
site. Complete LOH was detected in 3 tumour samples: in one case
there was loss of haplotype II from a I/II heterozygote, in another,
loss of VI from a II/VI heterozygote while the other was loss of I,
from a I/II heterozygote (Figure 2A, B, C). The II/VI LOH sample
was from a tumour with gastric mucosa phenotype. It is assumed
that these allelic losses represent a loss of a moderate to large
chromosomal fragment, but since none of these individual LOH
cases were heterozygous at both of the two outer polymorphic
sites, G545C and G1655A, it is impossible to determine whether
there is loss of the entire CDX2 gene. 
Clinicopathological correlation with haplotype 
Association between haplotype and the Dukes’ stage assignment
of the tumours was investigated (Table 4). A three by three c2 test
was performed by pooling data for haplotypes III to IX eliminating
the large number of cells with expected frequencies of less than 5
(16% of cells with E , 5). A significant association was observed
(P = 0.0066, c2 = 14.22, df = 4). This can be attributed to the high
frequency of haplotype I in Dukes’ stage C cases, haplotype II in
Dukes’ stage A cases and the remaining rare haplotypes, when
pooled together, in Dukes’ stage B cases (see Table 4). It is diffi-
cult to be certain how much value to put upon this finding since the
numbers involved are small and the haplotypes do not vary in their
amino acid coding potential. However, further analysis using the
Monte Carlo ‘Clump’ test but excluding the intermediate class,
stage B samples (where there might be effects due to grouping of
rare haplotypes) generated a P value of 0.027 for the collapsed
data. It is relevant to note that while the difference in distribution
of haplotypes between CRC cases and controls is not statistically
significant there is a greater frequency of haplotype I amongst
CRC cases (37%) than controls (CEPH 26%, British controls 29%;
Table 3). 
No specific association was observed between haplotypes or
genotypes and the 4 cases with a tumour of gastric mucosa
phenotype, which were haplotypes I/II, II/VI, II/II and III/IV. 
Table 3 Frequency of haplotypes in CRC and control subjects 
Haplotypes CRC chromosomes Normal chromosomes
P1 P2 P3 P4 P5 P6 CEPH British controls 
I G T T T G G 31 (37) 25 (26) 18 (29) 
II G C T T G A 28 (33) 37 (39) 32 (52) 
III G C A C T G 14 (17) 16 (17) 08 (13) 
IV G C A T G G 02 (2) 08 (8)  – 
V G T T T G A 01 (1) 02 (2)  – 
VI G C T T G G 03 (4) –  01 (2) 
VII G C A C T A – 01 (1)  – 
VIII C C T T G A 03 (4) 05 (5) 03 (5) 
IX G C A T G A 02 (2) 02 (2)  – 
Total 84 96 62 
P1 to P6 represents the following polymorphic sites: G545C; C-32T; A-31T; T1239C; G1314T; G1655A. The haplotypes have
been assigned Roman numerals I to IX. Percentage frequency is given in brackets. 
Table 4 Haplotype frequency in CRC individuals assigned with Dukes’ stage classification 
Haplotype Dukes’ stage classification 
P1 P2 P3 P4 P5  P6 A B C (C, C1 and C2) 
I G T T T G G 03 (21.4) 05 (27.8) 13 (59.1) 
II G C T T G A 09 (64.3) 05 (27.8) 06 (27.3) 
III G C A C T G 01 (7.15) 03 (16.7) 02 (9.1) 
IV G C A T G G – 01 (5.6) –
V G T T T G A – – 01 (4.5) 
VI G C T T G G 01 (7.15) –  – 
VIII C C T T G A – 02 (11.1) – 
IX G C A T G A – 02 (11.1) – 
Total 14 18 22 
P1 to P6 represents the following polymorphic sites: G545C; C-32T; A-31T; T1239C; G1314T; G1655A. The haplotypes have
been assigned Roman numerals I to IX. Percentage frequency is given in brackets. Relative expression of common and variant alleles 
In addition to searching for mutations, we have explored the
possibility of assessing the relative expression of pairs of alleles
in mRNA derived from biopsy samples from individuals
heterozygous for CDX2 polymorphisms. Differences in the rela-
tive allelic expression in the tumour sample might indicate the
presence of mutations affecting transcription. The T1239C poly-
morphism was used as a marker in this preliminary investigation
of 7 CRC cases from whom biopsy mRNA was prepared. Common
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(A)
C-32T
NT
(B)
(C)
CT C
CT T
G1655A
NT
GA A
GA G
GA A
Figure 2 LOH analysis. Results depicting the LOH observed at polymorphic sites C-32T (shown as SSCP banding patterns) and G1655A (shown as Mwo I
digest) in three CRC tumour (T) tissue (A, B, C). The genotypes of the tumour and normal (N) DNA are shown below the corresponding SSCP and Mwo I
digest. The position of the bands corresponding to lost alleles are indicated with arrows 
Cb1
Cc1
Cb2
Cp
Cc2
Cb3
Cc3
Tc1
Tb1
Tc2
Tb2
Tp
Tc3
Tb3
0.5 0.5
0.5 0.5
C AG T A C G T
N Case 1 T
0.5 0.5
0.5 0.5
Allele T
Allele C
C AG T A C G T
N Case 2 T
0.6 0.4
0.4 0.6
C AG T A C G T
N Case 3 T
0.4 0.7
0.6 0.3
C AG T A C G T
N Case 4 T
Figure 3 Relative expression of normal and variant alleles at the T1239C polymorphic site in 4 normal (N)/tumour (T) tissue pairs. The relative proportion
contributed by each allele, was determined using the following formula: %C = x(Cp – Cb)/[(Tp – Tb) + x(Cp – Cb)], where Tp and Cp are the PSL/mm2 values of the
normal and variant allele bands. Tb and Cb are the average of three background PSL/mm2 readings (e.g. Cb1, Cb2, Cb3) and Tc and Cc are the average of three
non-variant C or T PSL/mm2 readings (e.g. Cc1, Cc2, Cc3) from the appropriate lane. x is the control factor for gel lane to lane variation and is determined using
the following equation: (Tc – Tb)/(Cc – Cb)224 S Sivagnanasundaram et al
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and variant alleles at this site were assessed semi-quantitatively by
sequence analysis and phosphoimaging using a procedure
(formulated in the caption to Figure 3) which takes into account
the background PSL/mm2 reading at 3 blank positions and at 3
non-variant, control, bands in each lane. In this way appropriate
correction for background signal intensity and gel lane to lane
variation was made. In addition the relative levels in the tumour
versus the normal mRNA samples were compared. Some varia-
tion in the estimates of expression was seen in all samples tested
but all fell within the range of 0.3 to 0.7 (expected is 0.5 where
both alleles are equally expressed). Typical analyses for 4
tumour/normal pairs are shown in Figure 3. In case 4, one of the
pair of alleles is at a relatively low level (allele C = 0.3) in the
tumour sample only, and it is tempting to speculate that this
might indicate the presence of unidentified sequence variation
affecting gene transcription. It would be unwise to draw conclu-
sions from this limited data set, however, our data suggests that
this is a technique worth exploring further in the context of
cancer aetiology. 
DISCUSSION 
In this study, we have investigated the caudal-type homeobox
gene, CDX2, as a potential candidate gene in sporadic colorectal
tumorigenesis. We identified 6 sequence polymorphisms in
the human  CDX2 gene; however there were no differences in the
frequency of variant alleles between controls and CRC cases.
Evidence has emerged which suggests that CDX2 plays a
contributory role in tumour progression although there is no
evidence for a significant role in tumour initiation. LOH was
found in 3 out of 28 informative cases in our study of UK CRC
cases. This incidence of LOH is similar to that described for
Japanese sporadic CRC cases (2/20, Yagi et al, 1999). If our data
and those of Yagi et al (1999) are combined it appears that
approximately 10% of CRC tumour progression involves the loss
of CDX2. 
In addition, a statistically significant association was found
between Dukes’ stage histopathology and CDX2 haplotype which
suggests that haplotype I could be a predisposing factor for
advanced tumour progression. It is clearly important to verify this
finding in a larger tumour cohort. It is unfortunate that although
the Dukes’ stages were recorded for the tumour cohort examined
by Wicking et al (1998), CDX2 haplotypes were not derived and
association with tumour progression was not investigated. The
association between haplotype and tumour progression, if real,
must be due to mutations which affect the level of cellular CDX2,
although the difference in levels might be only marginal. There is
evidence from studies of mice carrying the Cdx2 null alleles of a
dose-dependent response to Cdx2 transcriptional regulatory
activity at the cellular level. It can be envisaged that mutations
that subtly alter the activity of Cdx2 may not be significant in the
normal epithelial cell but fast dividing neoplastic cells may be
much more vulnerable to small changes in Cdx2 levels. One inter-
pretation of our association study is that the presence of haplotype
II may predict a less aggressive tumour and a better outcome for
the patient while the presence of haplotype I predicts a more inva-
sive tumour and worse outcome. If these mutations are features of
particular haplotypes then they must lie in sequences outside
those examined here, since the sequence variants which comprise
the haplotypes appear not to affect RNA structure or protein
function. 
It was of particular interest to investigate those tumours in our
patient set that showed a gastric mucosa phenotype since their
appearance is similar to that of the heterotopic polyps found in the
Cdx2 heterozygous knockout mice. One of the 4 showed LOH of
CDX2 and another a rare variant in the 3¢-UTR of CDX2. While
the significance of these observations is uncertain they are never-
theless intriguing. 
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